- Identification of Potent and Selective RIPK2 Inhibitors for the Treatment of Inflammatory Diseases
-
NOD2 (nucleotide-binding oligomerization domain-containing protein 2) is an internal pattern recognition receptor that recognizes bacterial peptidoglycan and stimulates host immune responses. Dysfunction of NOD2 pathway has been associated with a number of autoinflammatory disorders. To date, direct inhibitors of NOD2 have not been described due to technical challenges of targeting the oligomeric protein complex. Receptor interacting protein kinase 2 (RIPK2) is an intracellular serine/threonine/tyrosine kinase, a key signaling partner, and an obligate kinase for NOD2. As such, RIPK2 represents an attractive target to probe the pathological roles of NOD2 pathway. To search for selective RIPK2 inhibitors, we employed virtual library screening (VLS) and structure based design that eventually led to a potent and selective RIPK2 inhibitor 8 with excellent oral bioavailability, which was used to evaluate the effects of inhibition of RIPK2 in various in vitro assays and ex vivo and in vivo pharmacodynamic models.
- He, Xiaohui,Da Ros, Sara,Nelson, John,Zhu, Xuefeng,Jiang, Tao,Okram, Barun,Jiang, Songchun,Michellys, Pierre-Yves,Iskandar, Maya,Espinola, Sheryll,Jia, Yong,Bursulaya, Badry,Kreusch, Andreas,Gao, Mu-Yun,Spraggon, Glen,Baaten, Janine,Clemmer, Leah,Meeusen, Shelly,Huang, David,Hill, Robert,Nguyen-Tran, Van,Fathman, John,Liu, Bo,Tuntland, Tove,Gordon, Perry,Hollenbeck, Thomas,Ng, Kenneth,Shi, Jian,Bordone, Laura,Liu, Hong
-
-
Read Online
- Fluorine-controlled C-H borylation of arenes catalyzed by a PSiN-pincer platinum complex
-
An efficient, regioselective synthesis of fluorine-substituted arylboronic esters was achieved through fluorine-controlled C-H borylation of arenes with diboron catalyzed by a PSiN-platinum complex. The promising utility of the PSiN-platinum catalyst and its unique regioselectivity were demonstrated for the first time, which would complement the well-developed Ir-catalyzed C-H borylation.
- Takaya, Jun,Ito, Shisei,Nomoto, Hironori,Saito, Narumasa,Kirai, Naohiro,Iwasawa, Nobuharu
-
supporting information
p. 17662 - 17665
(2015/12/18)
-
- INHIBITORS OF THE KYNURENINE PATHWAY
-
The present application provides novel inhibitors of indoleamine 2,3-dioxygenase-1 and/or indoleamine 2,3-dioxygenase-2 and/or tryptophan 2,3-dioxygenase, metabolites thereof, and phannaceutically acceptable salts or prodrugs thereof. Also provided are methods for preparing these compounds. A therapeutically effective amount of one or more of the compounds of formula (I) is useful in treating diseases resulting from dysregulation of the kynurenine pathway. Compounds of formula (I) act by inhibiting the enzymatic activity or expression of indoleamine 2,3-dioxygenase-1 and/or indoleamine 2,3-dioxygenase-2 and/or tryptophan 2,3-dioxygenase.
- -
-
Page/Page column 206; 207
(2014/12/12)
-